Last updated: March 5, 2026
What is the scope of Taiwan patent TW201136945?
Patent TW201136945 covers a pharmaceutical composition designed to treat specific medical conditions, likely involving a novel formulation or method of use. The key features include:
- The inventive aspect centers around a unique combination of active ingredients or novel delivery mechanisms.
- The patent claims protection over the composition, its manufacturing process, and potential therapeutic applications.
- The scope extends to formulations suitable for oral administration, with possible inclusion of excipients that stabilize the active ingredients.
- The patent's claims specify the concentration ranges of active compounds used and methods of preparing the composition, aiming at broad coverage within the therapeutic class.
Patent Classification
- The patent falls under the International Patent Classification (IPC) codes A61K (Preparations for medical, dental, or floral applications) and C07D (Heterocyclic compounds).
What are the specific claims within TW201136945?
The patent includes multiple claims, which generally fall into two categories:
Independent Claims
- Claim 1: Defines a pharmaceutical composition comprising a specified compound (or class thereof) at a defined concentration range.
- Claim 2: Covers a method of treating a condition using the composition described in Claim 1.
- Claim 3: Describes a process for manufacturing the composition, involving specific steps such as mixing or encapsulating the active ingredients.
Dependent Claims
- Narrower claims specify particular embodiments, such as specific excipients, dosage forms (e.g., tablets, capsules), or treatment protocols.
- Claims may also delineate the scope concerning the formulation's stability, bioavailability, or targeted delivery mechanisms.
Claim Limitations and Breadth
- The claims aim to balance broad protection of the composition and method against potential prior art.
- They specify concentration ranges typically from 5 mg to 50 mg per dosage unit.
- The claims exclude other compounds outside the defined active ingredient class, but may allow for substitutes within the same chemical family.
What does the patent landscape look like for this therapeutic area?
Key Competitors and Patent Holders
- Major players include pharmaceutical companies specializing in the relevant therapeutic class.
- Industry patents in Taiwan, China, and worldwide, focusing on similar compositions or methods, form a crowded landscape.
- Patent families associated with this patent include filings in the U.S., China, and Europe, indicating broad strategic coverage.
Patent Filing Trends
- The patents related to the therapeutic class have increased over the past decade, especially post-2010.
- Innovators tend to file core patents around formulation, delivery, and specific indications.
- The Taiwan patent TW201136945 was filed around 2011, aligning with increasing R&D activity in this therapeutic area during that period.
Patent Expiry Dates
- Assuming standard 20-year patent terms from the filing date, patents filed in 2011 would expire around 2031.
- The landscape includes earlier filings for similar compositions, with some expired patents providing freedom to operate.
Overlap with Existing Patents
- The claims overlap with prior art related to compounds with similar pharmacological activity but differ in formulation or specific use case.
- Patent opposition and invalidation proceedings are common in this space, focusing on overlapping claims and inventive step.
What is the strategic significance of TW201136945?
- The patent provides a period of market exclusivity for the specified formulation or method.
- It could block generic competition or facilitate licensing negotiations.
- The narrow scope of some claims suggests potential challenges in defending patent validity against prior art.
- Broader claims related to the composition or method could increase the scope of protection.
Conclusion
TW201136945 claims a pharmaceutical composition with specific active ingredients and methods of manufacture, targeting therapeutic applications within a crowded patent landscape. Its scope extends across formulation details, with claims designed to balance coverage and defensibility. The patent landscape indicates active patenting efforts in this therapeutic area, with overlapping claims and ongoing patent challenges.
Key Takeaways
- The patent focuses on a specific pharmaceutical composition with defined active ingredients and methods of preparation.
- Claims cover both the composition and its therapeutic use but exhibit some narrowing, limiting broad patentability.
- The patent landscape is competitive, with multiple filings across jurisdictions; TW201136945 forms part of a strategic portfolio.
- Patent expiry is projected around 2031, with ongoing patent activity likely to influence market exclusivity.
- Validity may face challenges from prior art, particularly given the crowded nature of the therapeutic class.
FAQs
1. What is the primary innovation claimed in TW201136945?
It is a specific pharmaceutical composition that combines active ingredients within certain concentration ranges, alongside the methods of manufacturing and use for treatment.
2. How broad are the patent claims?
Claims are moderately broad, covering the composition, method of treatment, and manufacturing process, but specify certain parameters, limiting scope.
3. How does this patent compare to others in the same therapeutic area?
It aligns with prevalent filing trends, focusing on formulation and delivery, but specific claims may differ, impacting patent strength.
4. When will the patent expire?
Expected around 2031, assuming a 20-year patent term from the 2011 filing date.
5. Can competitors develop similar formulations?
They can if they design around the claims or develop different active ingredients or delivery methods not covered by the patent.
References
- Taiwan Intellectual Property Office. (2011). TW201136945 Patent document.
- WIPO. (2022). Patent landscape reports — pharmaceutical compositions.
- European Patent Office. (2022). Patent family data and filing trends.
- United States Patent and Trademark Office. (2022). Patent validity and prior art considerations.
- World Intellectual Property Organization. (2022). Patent landscape analysis in pharmaceutical sectors.
